23andMe (ME) Competitors $3.56 -0.03 (-0.70%) As of 01:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ME vs. TERN, ETON, CYRX, RGNX, ALMS, CMPX, VALN, GLUE, KRRO, and NMRAShould you be buying 23andMe stock or one of its competitors? The main competitors of 23andMe include Terns Pharmaceuticals (TERN), Eton Pharmaceuticals (ETON), Cryoport (CYRX), REGENXBIO (RGNX), Alumis (ALMS), Compass Therapeutics (CMPX), Valneva (VALN), Monte Rosa Therapeutics (GLUE), Korro Bio (KRRO), and Neumora Therapeutics (NMRA). These companies are all part of the "pharmaceutical products" industry. 23andMe vs. Terns Pharmaceuticals Eton Pharmaceuticals Cryoport REGENXBIO Alumis Compass Therapeutics Valneva Monte Rosa Therapeutics Korro Bio Neumora Therapeutics Terns Pharmaceuticals (NASDAQ:TERN) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Is TERN or ME more profitable? Terns Pharmaceuticals has a net margin of 0.00% compared to 23andMe's net margin of -318.39%. Terns Pharmaceuticals' return on equity of -32.76% beat 23andMe's return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -32.76% -31.33% 23andMe -318.39%-129.98%-62.37% Which has higher valuation and earnings, TERN or ME? Terns Pharmaceuticals has higher earnings, but lower revenue than 23andMe. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$90.21M-$1.18-4.0223andMe$219.64M0.42-$666.70M-$25.32-0.14 Which has more risk and volatility, TERN or ME? Terns Pharmaceuticals has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Do institutionals & insiders hold more shares of TERN or ME? 98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 36.1% of 23andMe shares are held by institutional investors. 15.1% of Terns Pharmaceuticals shares are held by company insiders. Comparatively, 26.3% of 23andMe shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer TERN or ME? Terns Pharmaceuticals received 30 more outperform votes than 23andMe when rated by MarketBeat users. Likewise, 60.87% of users gave Terns Pharmaceuticals an outperform vote while only 54.55% of users gave 23andMe an outperform vote. CompanyUnderperformOutperformTerns PharmaceuticalsOutperform Votes4260.87% Underperform Votes2739.13% 23andMeOutperform Votes1254.55% Underperform Votes1045.45% Do analysts prefer TERN or ME? Terns Pharmaceuticals currently has a consensus target price of $18.30, indicating a potential upside of 285.51%. 23andMe has a consensus target price of $9.40, indicating a potential upside of 164.42%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Terns Pharmaceuticals is more favorable than 23andMe.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.8023andMe 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Does the media favor TERN or ME? In the previous week, 23andMe had 7 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 7 mentions for 23andMe and 0 mentions for Terns Pharmaceuticals. 23andMe's average media sentiment score of 0.00 beat Terns Pharmaceuticals' score of 0.00 indicating that 23andMe is being referred to more favorably in the news media. Company Overall Sentiment Terns Pharmaceuticals Neutral 23andMe Neutral SummaryTerns Pharmaceuticals beats 23andMe on 11 of the 17 factors compared between the two stocks. Get 23andMe News Delivered to You Automatically Sign up to receive the latest news and ratings for ME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ME vs. The Competition Export to ExcelMetric23andMePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$94.29M$6.54B$5.37B$9.12BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A5.6666.7714.56Price / Sales0.43357.981,264.1585.80Price / Cash1.2222.3236.0932.90Price / Book0.475.074.964.69Net Income-$666.70M$154.90M$117.89M$224.57M7 Day Performance4.99%1.33%1.76%1.69%1 Month Performance9.48%1.51%3.71%5.34%1 Year Performance-75.22%4.60%26.11%21.47% 23andMe Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ME23andMe1.4224 of 5 stars$3.56-0.7%$9.40+164.4%-74.8%$92.47M$219.64M-0.14770TERNTerns Pharmaceuticals3.7966 of 5 stars$4.43-1.6%$18.30+313.1%-8.4%$376.28MN/A-3.7540ETONEton Pharmaceuticals2.4676 of 5 stars$14.41+0.9%$18.67+29.5%+268.8%$375.38M$31.64M-65.5020CYRXCryoport3.4164 of 5 stars$7.50+0.1%$12.29+63.8%-43.5%$370.73M$226.11M-2.221,170News CoverageRGNXREGENXBIO4.3769 of 5 stars$7.37+3.1%$35.27+378.6%-44.8%$365.15M$84.33M-1.47370Analyst ForecastALMSAlumisN/A$7.66-1.7%$26.83+250.3%N/A$361.71MN/A0.00N/APositive NewsCMPXCompass Therapeutics3.0199 of 5 stars$2.60+4.0%$11.80+353.8%+87.8%$357.73MN/A-7.0320Short Interest ↑VALNValneva2.8875 of 5 stars$4.37+1.4%$18.50+323.3%-47.0%$355.11M$165.52M-33.62700News CoveragePositive NewsGLUEMonte Rosa Therapeutics2.6577 of 5 stars$5.66-1.7%$14.00+147.3%+12.7%$347.75MN/A-3.0990Short Interest ↑KRROKorro Bio1.5099 of 5 stars$37.00+0.1%$144.00+289.2%-8.5%$346.69MN/A0.0070NMRANeumora Therapeutics3.5178 of 5 stars$2.05-5.5%$16.50+704.9%-85.5%$331.20MN/A-1.10108 Related Companies and Tools Related Companies TERN Competitors ETON Competitors CYRX Competitors RGNX Competitors ALMS Competitors CMPX Competitors VALN Competitors GLUE Competitors KRRO Competitors NMRA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ME) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share 23andMe With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ME Stock Alerts